Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.

By S. Moghimi, J. Szebeni. Progress in lipid research, 2003

1,202 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review (2018, background): “Unfortunately, PEGylation reduces the drug uptake significantly by the cells [21,22].”
Nanoparticles: pharmacological and toxicological significance (2007, background): “Stealth liposomes have the ability to evade the interception by the immune systems, and therefore, have longer half-life (Moghimi and Szebeni, 2003).”
Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “in nanoparticle stability and the opsonization process (24,31,32).”
The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “It is not the objective of this review to cover surface modification strategies, (see refs, [33,35,67,68] for more information on this topic) but PEGylation still remains today the gold standard to impart CDCs with long circulation times [69,70].”
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. (2006, background): “Alternatively, some theories have implied that PEGylated nanoparticles, added in excess, simply overload the opsonization and clearance systems of the body, thereby giving the particles the false appearance of stealth properties (Moghimi and Szebeni, 2003).”